The Considered to Introduce Drug-Tech Combos for Closed Loop Medicine
Healthcare marketing agency The Considered is launching the brand platform for Closed Loop Medicine, the global leader in the development of single-prescription drug plus digital therapy (DTx) combination products. The startup is developing drug and digital therapy combinations, focused on dose optimization, to treat insomnia and hypertension.
David Hunt, CEO of The Considered, says his independent agency is allowing him to leverage more than twenty years of experience working for Big Pharma for new, cutting-edge technological solutions like Closed Loop Medicine. “There are recurring problems,” he says, “particularly around how you can bring more value to the patient, how you can help them to build brand equity, and how you can really use technology in particular to improve outcomes.”
A company like Closed Loop Medicine, he explains, is “providing the solution to some of the most consistent challenges I’ve seen in Pharma over the last 5 or 10 years.”
There’s been a lot of talk around the pill and going beyond the pill, but “there’s been a lot less impact and action,” says Hunt.
“We’re delighted to have Closed Loop as another confirmed client,” explains Hunt. “It’s another example of that kind of innovative organization, where we’re looking to support, to drive new thinking, be courageous, use experimentation and break a few rules.”
Dr. Myles Furnace, Commercial VP for Closed Loop Medicine, shared, “We are developing drug therapy and digital therapeutic combination products with the ambition to transform care at the patient level through precision dosing. We’re thrilled to be working alongside The Considered to bring our innovative approach to the US market.”
Hunt explains with the addition of Closed Loop Medicine, The Considered client roster grows to six. “We’re very, very happy with the cocktail of clients we have because it allows us to combine lots and lots of brilliant thinking over the years with fertile ground for experimentation, innovation,” he says.
The UK-based company recently closed $17 million of new investment from a range of top UK and European venture capital investors, bringing the total raised by the company to $30 million since it was founded in 2017.